PC
Pacira BioSciences, Inc.
PCRX · NASDAQ
$25.56 +3.99% (+$0.98)
1M -3.53%
Market Cap $968.8M
P/E Ratio 66.19x
Div. Yield -
ROE 2.13%
Bulios Fair Price
$25.92
1.4% upside
Current Price
$25.56
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PCRX is currently trading close to its fair value. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
8/9Valuation
70 /100
Cheap P/E 66.19x
EV/EBITDA 10.24x
P/FCF 5.40x
Growth
25 /100
Declining EPS growth 22.22%
Rev. growth 2.89%
Book val. growth 3.65%
Profitability
57 /100
Moderate Gross margin 79.21%
Net margin 1.96%
FCF margin 24.06%
Quality
13 /100
Poor ROIC 1.35%
ROE 2.13%
Asset turnover 0.60x
Debt
66 /100
Moderate Debt/Equity 0.61x
Current ratio 5.04x
Net debt/EBITDA 1.80x
Stability
37 /100
Moderate Beta 0.27x
Rev. volatility 1.46%
Profitable years 1
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PCRX
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Frank D. Lee
Employees
827
Headquarters
Brisbane
Upcoming events
05 NOV
Earnings
Upcoming earnings report